Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

Evolus Earnings Call: Key Takeaways

Evolus delivered its fourth consecutive positive adjusted EBITDA quarter, demonstrating strong operating leverage as revenue grew 13% while non-GAAP operating expenses remained disciplined.

Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Revenue GrowthGlobal revenue up 13% to $78M; Jeuveau global toxin up 11%.
Mgmt ConfidenceHigh confidence in 2028 objectives and portfolio strategy execution.
Demand VisibilityHealthy aesthetics market; GLP-1 therapies driving new patient adoption.
Margin TrendsAdjusted gross margin 66.1%; full-year guidance 67% to 67.5%.
Op. LeverageRevenue grew 14% year-to-date while non-GAAP expenses fell 2.5%.
Pricing PowerPortfolio growth rebates and bundling pilots driving deeper account penetration.
Vol vs PriceGrowth driven by 500 new accounts and 23% rewards membership increase.
Segment GrowthHA business grew nearly 40% in Q3 and 50% year-to-date.
New ClientsAdded over 500 purchasing accounts; cumulative base exceeds 19,000 customers.
Capex & DebtEnded quarter with $41.7M cash; $120M additional non-GAAP capacity available.
RegulatoryFDA untitled letter for Instagram post; Sculpt approval expected Q4 2026.
CommentaryShifted from single-product company to a diversified global performance beauty platform.
New LaunchesEvolus Sculpt (2027), Lifts (2028), and Profilo (2030) planned launches.

Growth

Global revenue grew 13% to $78M; HA business grew nearly 40% in Q3.

Outlook

Reaffirmed 2028 targets of $450M-$500M revenue and 13%-15% adjusted EBITDA margins.

Risks

Management received an FDA untitled letter regarding an Instagram post; seasonal Q3 softness noted.

Source

The company's earnings call, NASDAQ: EOLS, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

Evolus, Inc.: key numbers

Share price
$6.63Close, Nov 16
Market cap
$439M
Shares outstanding
66.19MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Evolus, Inc.

All →
4:58 PM ET 10-Q
Financial Results ▶ Call

Evolus Q3 2026 Results: Net Loss of $12.5M, Loss Narrows

Evolus, Inc. is an aesthetic neurotoxin company that has incurred significant losses since inception and relies heavily on its licensing agreements with Daewoong and Symatese. The company is currently focused on the commercial success of Jeuveau and the regulatory approval process for its Evolysse product line.

Key figure
Net loss $12.5M
4:12 PM ET 8-K
Financial Results

Evolus Financial Results

Evolus reported Q3 2026 global net revenue of $78.0 million, a 13% increase year-over-year, driven by growth in its Jeuveau toxin and HA gel portfolio. The company achieved its fourth consecutive quarter of positive Adjusted EBITDA at $1.2 million and reaffirmed its full-year 2026 revenue guidance of $330 million to $337 million.

Term
Q3 2026

“Our third quarter results demonstrate the continued strength of our commercial execution and the progress we are making in building a diversified global performance beauty company. Jeuveau® remains a durable growth engine, and our hyaluronic acid (HA) gel portfolio is gaining meaningful share and becoming an increasingly important contributor to the business.”

David Moatazedi, President and Chief Executive Officer

“Along with our commercial progress, we are building a robust innovation pipeline that broadens our long-term opportunity. Our partnership with IBSA to develop and commercialize Profhilo® in the United States establishes the foundation for skin quality as a third category within our facial injectable platform.”

David Moatazedi, President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.